StreetInsider.com News Articles

aTyr Pharma to present efzofitimod subgroup data at WASOG 2026

Wed, 15 Jul 2026 08:00:33 -0400

aTyr Pharma, Inc. (Nasdaq: ATYR) announced it will present a subgroup analysis of its Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis at the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) 2026 Congress, held July 15–17, 2026, in Porto, Portugal.

The poster presentation, scheduled for July 16, 2026, focuses on a subset of 44 patients from the broader EFZO-FIT™ trial who had restrictive lung disease, defined as forced vital capacity percent predicted (FVCpp) of 80% or below with an FEV1/FVC ratio of 0.7 or above. The full EFZO-FIT™ trial enrolled 264 pulmonary sarcoidosis patients across all lung phenotypes.

aTyr Pharma to present efzofitimod subgroup data at WASOG 2026

Wed, 15 Jul 2026 08:00:33 -0400

aTyr Pharma to present efzofitimod subgroup data at WASOG 2026

Wed, 15 Jul 2026 08:00:33 -0400

aTyr Pharma to present efzofitimod subgroup data at WASOG 2026

Wed, 15 Jul 2026 08:00:33 -0400

aTyr Pharma to Present Subgroup Analysis of Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis at WASOG 2026

Wed, 15 Jul 2026 08:00:00 -0400

Patients with restrictive lung disease demonstrate clinically meaningful benefit in FVC and improvements in multiple PROs for 5.0 mg/kg efzofitimod compared to placebo.

Company submitted protocol to FDA in June 2026 for planned Phase 3 study of efzofitimod in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease.

SAN DIEGO, July 15, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Company will

aTyr Pharma to Present Subgroup Analysis of Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis at WASOG 2026

Wed, 15 Jul 2026 08:00:00 -0400

Patients with restrictive lung disease demonstrate clinically meaningful benefit in FVC and improvements in multiple PROs for 5.0 mg/kg efzofitimod compared to placebo.

Company submitted protocol to FDA in June 2026 for planned Phase 3 study of efzofitimod in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease.

aTyr Pharma to Present Subgroup Analysis of Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis at WASOG 2026

Wed, 15 Jul 2026 08:00:00 -0400

Patients with restrictive lung disease demonstrate clinically meaningful benefit in FVC and improvements in multiple PROs for 5.0 mg/kg efzofitimod compared to placebo.

Company submitted protocol to FDA in June 2026 for planned Phase 3 study of efzofitimod in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease.

aTyr Pharma to Present Subgroup Analysis of Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis at WASOG 2026

Wed, 15 Jul 2026 08:00:00 -0400

Patients with restrictive lung disease demonstrate clinically meaningful benefit in FVC and improvements in multiple PROs for 5.0 mg/kg efzofitimod compared to placebo.

Company submitted protocol to FDA in June 2026 for planned Phase 3 study of efzofitimod in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease.

aTyr Pharma to Present Subgroup Analysis of Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis at WASOG 2026

Wed, 15 Jul 2026 08:00:00 -0400

Patients with restrictive lung disease demonstrate clinically meaningful benefit in FVC and improvements in multiple PROs for 5.0 mg/kg efzofitimod compared to placebo.

Company submitted protocol to FDA in June 2026 for planned Phase 3 study of efzofitimod in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease.

aTyr Pharma to Present Subgroup Analysis of Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis at WASOG 2026

Wed, 15 Jul 2026 08:00:00 -0400

Patients with restrictive lung disease demonstrate clinically meaningful benefit in FVC and improvements in multiple PROs for 5.0 mg/kg efzofitimod compared to placebo.

Company submitted protocol to FDA in June 2026 for planned Phase 3 study of efzofitimod in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease.

aTyr Pharma to Present Subgroup Analysis of Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis at WASOG 2026

Wed, 15 Jul 2026 08:00:00 -0400

Patients with restrictive lung disease demonstrate clinically meaningful benefit in FVC and improvements in multiple PROs for 5.0 mg/kg efzofitimod compared to placebo.

Company submitted protocol to FDA in June 2026 for planned Phase 3 study of efzofitimod in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease.

aTyr Pharma to Present Subgroup Analysis of Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis at WASOG 2026

Wed, 15 Jul 2026 08:00:00 -0400

Patients with restrictive lung disease demonstrate clinically meaningful benefit in FVC and improvements in multiple PROs for 5.0 mg/kg efzofitimod compared to placebo.

Company submitted protocol to FDA in June 2026 for planned Phase 3 study of efzofitimod in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease.

Form SCHEDULE 13G/A aTYR PHARMA INC Filed by: FEDERATED HERMES, INC.

Wed, 08 Jul 2026 07:37:00 -0400

si-local-file:///var/storage/secattach/20260708/26744288.html

Form SCHEDULE 13G/A aTYR PHARMA INC Filed by: FEDERATED HERMES, INC.

Wed, 08 Jul 2026 07:37:00 -0400

si-local-file:///var/storage/secattach/20260708/26744288.html

Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing

Fri, 26 Jun 2026 08:35:00 -0400

NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the June 24^th & 25^th Life Sciences Virtual Investor Forum are now available for on-demand viewing.

REGISTER AND VIEW PRESENTATIONS HERE

Select companies are accepting 1x1 management meeting requests through June 19^th. Please Schedule 1x1 Meetings here.